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Abstract: Bone allograft is the most widely accepted approach in treating patients suffering from large 
segmental bone defect regardless of the advancement of synthetic bone substitutes[ I, 2]. However, the 
long-term complications of allograft application in term of delayed union or even nonunion were 
reported due to the stringent sterilization process prior to clinical implantation[3, 4]. Our previous 
studies demonstrated that the incorporation of magnesium ions (Mg2+) into biomaterials could 
significantly promote the gene up-regulation of osteoblasts and new bone formation in animal model[5, 
6]. Hence, our group has proposed to implant Mg2+ into bone allograft by adopting plasma ions 
immersion implantation and deposition (PIII&D) approach. 
The decellularization and gamma irradiation process were performed on bovine bone allograft prepared 
in I x 1 x 0.1cm. Subsequently, a thin layer of magnesium coating was prepared by using magnesium 
PIII&D technique. The surface morphology, elemental chemical and depth of the samples were 
examined by scanning electron microscopy (SEM), energy dispersive x-ray spectroscopy (EDS) and 
x-ray photoelectron spectroscopy (XPS), respectively. The cytotoxicity, cell morphology, proliferation 
and alkaline phosphatase (ALP) expression of magnesium-enriched bone allografts were evaluated by 
culturing human immortalized mesenchymal stem cells (hTMSC). 
With the adjustment of implantation parameters e.g. voltage and time, the magnesium composite layer 
had been successfully established on the surface of allogenic bone. The thickness of the composite 
layer ranged from 500nm to -800nm. The surface topography of allograft flattened and the 
microstructure of collagen fibers structure was also changed after plasma treatment. The cells elongated 
on the surfaces of plasma treated and untreated samples though. The cell viability in magnesium 
plasma modified allograft was significantly higher than that of the control. The ALP gene expression of 
hTMSCs in the group of PIII&D treated samples was highly up-regulated. However, there was no 
significant difference between plasma treated group and the control in terms of cell proliferation rate. 
The magnesium plasma ion immersion implantation and deposition technique has been first applied to 
bone allograft. Indeed, this well-developed technology is able to alter the surface properties of 
materials, while the bulk mechanical properties maintained[7]. The in vitro results suggested that the 
modified allografts could up-regulate the ALP gene activity and cell viability of htMSCs. Hence, it is 
believed that the original mechanical properties of bone allograft should be maintained, when its 
bioactivity enhanced. Further experiments including in-depth molecular cell biological and animal 
studies should be initiated prior to clinical application. 
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